Multiple Endocrine Neoplasia Clinical Trial
Official title:
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients
Objectives:
The aim of the present study is to assess the significance of metabolomics and genetics in
diagnosing and survival evaluation for pNET in the periodic follow-up of MEN1 patients.
Aim 1: To evaluate the relationship of serum global metabolic profiles with subsequent
development of aggressive PNET and evaluate patients survival in a nested case-control study
of MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have
developed non-aggressive PNETs (controls).
Aim 2: Validate the top serum metabolites identified from Aim 1 in MEN1 patients who have
developed aggressive PNETs and MEN1 patients who have developed non-aggressive PNETs, using a
targeted metabolomics approach.
Aim 3: Prospectively identify the potential miRNA biomarkers of serum with miRNA sequencing
in MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have
developed non-aggressive PNETs (controls).
Aim 4: Validate the potential miRNA biomarkers identified from Aim 1 in MEN1 patients who
have developed aggressive PNETs and in MEN1 patients who have developed non-aggressive PNETs,
using a targeted qRT-PCR approach (in serums), as well as to see the relationship of
potential miRNA biomarkers with patients survival.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03053999 -
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
|
||
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Completed |
NCT00501449 -
Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
|
||
| Terminated |
NCT00947167 -
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00204373 -
Treatment of Zollinger-Ellison Syndrome With Prevacid
|
Phase 4 | |
| Recruiting |
NCT05812573 -
A Retrospective Study for Multiple Endocrine Neoplasia
|
||
| Recruiting |
NCT03348501 -
Study and Follow-up of Multiple Endocrine Neoplasia Type 1
|
N/A | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT00990535 -
High Dose Somatostatin Analogues in Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00001277 -
Studies of Elevated Parathyroid Activity
|
Phase 2 | |
| Completed |
NCT00001345 -
Studies of Inherited Diseases of Metabolism
|